Malaria Targeted Parasite Elimination (TPE) Strategy

Partnership objective

The Namibian Ministry of Health and Social Services has committed to eliminating malaria by 2020. The Zambezi region in the North of the country is a particular focus area, as it is a high risk transmission area, accounting for a third of the total number of malaria diagnoses in the country.

The Novartis Foundation aims to work with partners to define the optimal strategy to interrupt malaria transmission, while building evidence on how TPE works and strengthening health surveillance and response capabilities. The Novartis Foundation aims to work with partners to define the optimal strategy to interrupt malaria transmission, while building evidence on how TPE works and strengthening health surveillance and response capabilities. Copyright Novartis Foundation

What are the health needs and challenges?

The Namibia Malaria Elimination Research Partnership (NAMEP) in Zambezi includes two phases: to understand malaria transmission and build capacity for surveillance and response; and to test innovative response strategies to eliminate malaria.

While Namibia has made significant progress in reducing malaria, reaching the stage of pre-elimination, it is now important to identify and treat malaria both in people with symptoms of malaria and in their asymptomatic contact persons. This strategy towards elimination is called targeted parasite elimination (TPE).

Description of partnership activities and how they address needs and challenges

The Novartis Foundation’s partners include the Global Health Group at the University of California, San Francisco, the University of Namibia, the National Vector Borne Disease Control Programme at the Namibian Ministry of Health and Social Services, the London School of Hygiene & Tropical Medicine and the Clinton Health Access Initiative.

The Novartis Foundation aims to work with partners to define the optimal strategy to interrupt malaria transmission, while building evidence on how TPE works and strengthening health surveillance and response capabilities. The next phase of intervention aims to reduce the malaria burden and to determine the effectiveness, operational feasibility, safety and cost-effectiveness of TPE. Results will be shared with the health authorities to inform Namibia’s approach to eliminating malaria.

Partnership information

Company(ies) Novartis

Partner(s) Clinton Health Access Initiative, Global Health Group at the University of California, San Francisco, London School of Hygiene and Tropical Medicine, National Vector-borne Disease Control Program, Namibia, University of Namibia

Type of Partner(s) Academia / Hospitals, Government, PDPs

Therapeutic Focus Infectious Diseases

Disease(s) Malaria

Program Type(s) Research & Development - Operations Research

Targeted Population(s) Children, General population, Health professionals, Mothers

Region(s) Sub-Saharan Africa

Number of Countries 1

Country(ies) Namibia

Start Date 2014

More information Novartis Foundation

Anticipated completion date Ongoing